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trials mixed these types in different (and even unstated) propor-
tions. Some (n = 12) required sinus rhythm for various durations
at randomization, increasing the chance of success; 4 ignored
early recurrences or allowed for recardioversion, while 16
counted every recurrence. In addition, methods used to detect
recurrence varied from ECG conﬁrmation at regularly scheduled
visits to much more sensitive trans-telephonic monitoring (n =
11), which was employed in differing ways. Furthermore, efﬁ-
cacy endpoints were affected by biased termination of follow-up,
as treatment withdrawal due to side effects leads to less detec-
tion of recurrence. Nevertheless, a published meta-analysis
ignored these differences, citing similar recurrence rates in
control groups and chi-squared tests that did not detect statisti-
cal heterogeneity. In our opinion, this does not adequately
address heterogeneity in study designs, and the resulting esti-
mates are unsuitable for economic modeling. CONCLUSION:
Strict adherence to frequentist views can lead to inappropriate
pooling of trial data and erroneous inputs for economic models.
A Bayesian perspective provides a more correct view of the
intractable study design differences.
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OBJECTIVES: Educating hypertensive patients in blood pressure
management can improve clinical outcomes. The BPSZ Program
is a nationwide educational program which provides participants
with tailored educational materials in addition to a complimen-
tary trial of one of three different antihypertensive medications.
The BPSZ-BLISS study is a naturalistic study to evaluate the
effectiveness of the BPSZ program by utilizing a sub-set of the
Program participants and measuring the following: blood pres-
sure (BP) control, compliance, persistence and treatment satis-
faction. METHODS: 20,000 MDs enrolled in the BPSZ Success
Zone program were invited to participate in the study. Using an
Interactive Voice Response System (IVRS), MDs report BP and
other data at the enrollment visit and at every usual care visit up
to 12 +/−2 months; subjects self-report BPs, persistence, compli-
ance and treatment satisfaction at 3, 6 and 12 months post BPSZ
enrollment. MDs and subjects are supported by call center rep-
resentatives as needed. In addition to BPSZ program enrollment
medication, MDs prescribe anti-hypertensive medications and
schedule visits as per usual care. The General Electric Health care
database will be used as an external referent to facilitate inter-
pretation of study outcomes. RESULTS: After 12 months, 2,000
IRB approved MDs have enrolled over 10,000 subjects (48%
male; mean age 56 years; 26% newly diagnosed); 97% of MDs,
and 75% of subjects successfully entered IVRS enrollment data.
Automated IVRS validations have successfully maintained
cohort integrity and data quality (less than 5% error on key
study variables). MD and patient enrollment will continue until
April 2007; study completion is scheduled for mid 2008. CON-
CLUSION: MD and patient enrollment, and the acquisition of
outcomes data in a nationwide health education program require
innovative design and automated data management and quality
control methodologies. Strengths and weaknesses of the BPSZ-
BLISS study design can help inform similar health education
program evaluation initiatives.
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OBJECTIVES: To compare mobile phone messaging and postal
reminders as means of increasing the attendance rate during the
ﬁrst 24 weeks of lipid-lowering therapy among hyperlipidemic
patients in primary care. METHODS: The study was a ran-
domized controlled trial of 918 patients from 19 family practice
clinics conducted between February 2003 and June 2005.
Patients were randomly assigned to receive mobile phone
message reminders, postal reminders, and control strategies. To
ascertain attendance rates, patients were regularly followed up
12 to 24 weeks after their treatment. Reminders were sent on
average at 16 weeks. The primary measure was the attendance
rate at 24 weeks. A secondary outcome was identifying the direct
cost and beneﬁts of each reminder type. RESULTS: Overall
attendance rate was 74.1%. This differed between groups, with
76.1% attendance for the mobile phone messaging group,
73.5% for postal reminders, and 72.4% for the control group.
According to a multivariate analysis, the mobile phone messag-
ing group had a signiﬁcantly higher attendance rate (OR 1.48,
95% CI: 1.01–2.16) than the control group, but the postal
reminder group (OR 1.15, 95% CI: 0.79–1.69) did not. More-
over, for one additional visit, the marginal cost of mobile phone
messaging (USD 3.1) was much lower than that of postal
reminders (USD 47.0). CONCLUSION: Mobile phone messag-
ing is a more cost-effective method to increase the attendance
rate at 24 weeks after lipid lowering therapy among hyperlipi-
demic patients.
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OBJECTIVES: To evaluate the ability of interactive voice recog-
nition (IVR) technology to improve statin adherence in a cohort
of new start patents. METHODS: Plan members were identiﬁed
based on the existence of a ﬁlled prescription for statin therapy
between May 1, 2005 and December 1, 2005 and randomized
to intervention or control group. Statin prescription claims were
evaluated through June 25, 2006 when study analysis was com-
pleted. Subjects had to be 18 years or older, continuously
enrolled in the health plan for 2 years, and new users of statin
therapy. Members enrolled in any other plan-sponsored IVR ini-
tiative were excluded from this analysis. The intervention group
received three automated phone calls; call one provided disease
state education, call two was a reﬁll reminder, and call three
addressed the importance of physician follow up. The program
provided customized interaction based on patient response,
primary vs. secondary prevention, and reﬁll behavior. Persistence
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and mean possession ratios (MPR) and were calculated at a 3–6
month timeframe for all study participants and compared to
usual care. RESULTS: During the 7-month enrollment period a
total of 6833 members were randomized to the intervention
group for call one, 3274 for call two, 772 for call three, and
4172 to usual care. Members reached for each intervention
group were 3723 for call one, 1427 for call two, and 339 for
call three. Targeted members demonstrated statistically signiﬁ-
cant higher rates of persistency compared to the control group
(49.2% vs 44.70%). MPRs were also statistically signiﬁcantly
higher for members receiving telephonic intervention at 3–6
months (0.759 vs 0.738). These differences were seen regardless
of age and gender. CONCLUSION: Compliance with statin
therapy remains poor, however IVR technology can improve
adherence to statins in new start patients. Additional studies are
needed to evaluate the use of IVR technology in combination
with other more traditional compliance methods.
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OBJECTIVES: To assess whether new users of antihypertensive
therapy could beneﬁt from using a single-pill, ﬁxed-dose combi-
nation drug compared with separate pills to improve their adher-
ence to therapy. METHODS: Data from the Integrated Primary
Care Information database in The Netherlands (NL) and 30
Italian (IT) general practitioners with automated medical records
were used. Patients aged ≥30 y with mild-to-moderate hyperten-
sion and ≥3 cardiovascular risk factors or prior cardiovascular
events who were experienced or new users of antihypertensives
in June 2003–June 2004 (NL) or June 2004-June 2005 (IT) were
selected. Patients were followed until October 2005 (NL) or Feb-
ruary 2006 (IT) when they completed a questionnaire concern-
ing adherence to their therapy. Treatment adherence (percentage
of days covered [PDC]) was also calculated from the prescrip-
tion records. RESULTS: A total of 729/1473 (49.5%) (NL) and
1320/1602 (82.4%) (IT) completed the questionnaire. Of these,
101 (NL) and 47 (IT) patients were new users of antihyperten-
sives. Reasons for not taking medications were side effects, inef-
fectiveness and forgetfulness, which scored highest in the NL. In
Italy, forgetfulness and side effects were ranked highest. The
median PDC for antihypertensive drugs was 57% (NL) and 69%
(IT), less than 40% (NL) and 42% (IT) had PDC > 80%. Partial
(PDC 20–80%) and poor (PDC < 20%) adherence occurred fre-
quently in newly treated hypertensive patients. Approximately
35% (NL) and 70% (IT) of the respondents stated that they
would be less or much less likely to miss a dose with a single pill
combination therapy. The likelihood to miss a dose with single-
pill treatment was not associated with the prescription-derived
PDC levels, but highly associated with self-reported level of
adherence. CONCLUSION: Patients newly treated with antihy-
pertensive drugs with additional cardiovascular risk factors may
beneﬁt from a single pill. Screening of those who may beneﬁt
should be based on self-reported adherence rather than PDC
levels.
PCV73
DESCRIBING DRUG USE PATTERNS USING SEQUENCE
ANALYSIS
Gause D, Lau H
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: Describe characteristics of drug prescribing pat-
terns of antihypertensive agents using sequence analysis. With
frequent changes in drug classes, sequence analysis can help illus-
trate the number and length of different drugs prescribed for
treatment. METHODS: Medstat’s MarketScan Database from
2003–2004 was used to identify a sample of newly diagnosed
hypertensive patients with 6 months continuous follow-up
administrative claims data. Drugs evaluated in each follow-up
month were ACEI, ARB, BB, CCB, diuretic, combination AHY
regimens, or none. For each patient, a sequence pattern is deﬁned
as an ordered list of drugs prescribed. Characteristics of patterns
are described and visualizations were made using index plots 
and parallel-coordinates plots. RESULTS: Eighty-seven different
sequences were identiﬁed among 387 patients studied. The three
most frequent sequences observed were 6 continuous months on
diuretic (16%), 6 months on ACE (14%), and 6 months on BB
(12%). Nineteen percent of patients had no drug after the ﬁrst
month, 40% had at least one month on “no” drug, and the
average duration on “no” drug was 1.4 (SE = 0.05) months.
Patients used an average of 1.7 (SE = 0.1) different drugs. Thirty-
eight percent of patients had some diuretic use and 15% had 6
months on diuretic. There were no signiﬁcant age or gender dif-
ferences in number and average length of drug episodes (a string
of months on same drug), but females had more and longer
episodes of “no” drug. Index plots with drug episodes charac-
terized by different colors show changes among diuretics occur
quicker and more frequently than among other drug classes.
CONCLUSION: Sequence analysis is used in many scientiﬁc
ﬁelds and is an unused tool that health economics can use for
summarizing changes in antihypertensive and other medications.
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OBJECTIVES: The purpose of this study was to validate the
health-related quality of life (HRQL) component of a hybrid
instrument IMPACT (Impact of Pharmacist Activities and Care
on Treatment outcomes) that is being developed to measure
patient satisfaction with pharmacist services and HRQL when
patients with multiple chronic conditions receive care in a phar-
macist-run medication therapy management (MTM) clinic.
METHODS: The HRQL component (developed following a 
systematic literature review and qualitative survey of patient 
and provider responses) had 24 items in ﬁve domains (physical,
social, emotional functioning, diet and medication-related
issues). The instrument was pretested on second year pharmacy
students at our institution to determine its psychometric prop-
erties (reliability, construct validity and responsiveness). Student
participants received the same baseline scenario (1) of a patient
with diabetes, hypertension and dyslipidemia and were random-
ized to receive one of two endings (2A or 2B). Scenario 2A
described patient status where a positive change in health status
occurred due to pharmacist intervention and Scenario 2B when
there was no change. Participants signed a consent form and
completed web-based pre and post HRQL surveys. Reliability
was tested using Cronbach’s alpha; responsiveness (sensitivity
